Breaking News Instant updates and real-time market news.

IONS

Ionis Pharmaceuticals

, BIIB

Biogen

$305.59

-0.4 (-0.13%)

07:22
10/10/16
10/10
07:22
10/10/16
07:22

Ionis drug likely to be approved rapidly, says Wells Fargo

After Ionis Pharmaceuticals (IONS) and partner Biogen (BIIB) reported detailed data for their RNA Therapeutic nusinersen, in patients with both symptomatic and pre-symptomatic type 1 Spinal Muscular Atrophy, as well as data for patients with type 2/3 Spinal Muscular Atrophy, or SMA, Wells Fargo says it expects the drug to be rapidly approved. The firm thinks that the FDA will approve "a broad label" covering pre-symptomatic and symptomatic type I SMA, as well as type 2/3 SMA. The firm says that the companies should have "a very large commercial opportunity," and it keeps an Outperform rating on Ionis.

IONS

Ionis Pharmaceuticals

BIIB

Biogen

$305.59

-0.4 (-0.13%)

  • 10

    Oct

  • 26

    Oct

  • 06

    Nov

IONS Ionis Pharmaceuticals

10/06/16
PIPR
10/06/16
NO CHANGE
Target $46
PIPR
Overweight
Piper thinks Alnylam failure is positive for Ionis
Piper Jaffay analyst Joshua Schimmer thinks Alnylam Pharmaceuticals' (ALNY) "abrupt halt" of revusiran for TTR cardiomyopathy is likely a positive for Ionis Pharmaceuticals' (IONS) transthyretin program. The move "knocks out a competitive drug" while Ionis and GlaxoSmithKline (GSK) remain on their previously indicated timeline, Schimmer tells investors in a research note. The analyst at this point believes Alnylam's setback will be limited to revusiran and not read-through to other Gal-Nac programs or other TTR cardiomyopathy or polyneuropathy programs. He keeps an Overweight rating on Ionis with a $46 price target,
10/06/16
RBCM
10/06/16
NO CHANGE
RBCM
Alnylam news not a negative read through on other RNAi drugs, says RBC Capital
After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, RBC Capital analyst Michael Yee does not thinks that the news indicates problems with all RNAi drugs. Rather, he thinks that RNAi was not the proper treatment for the disease that Alnylam was targeting. Other companies with RNAi treatments include The Medicines Company (MDCO0, Ionis Pharmaceuticals (IONS), Arrowhead (ARWR), and Arbutus Biopharma (ABUS).
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Ionis has no read through from negative Alnylam data, says Wells Fargo
After Ionis (IONS) competitor Alnylam Pharmaceuticals (ALNY) announced that it was terminating the development of its revusiran RNAi drug due to poor outcomes in clinical trials, Wells Fargo thinks that the news is "a significant positive" for Ionis because it eliminates a competitor. The firm says that Ionis' drug is significantly different than Alnylam's product, and it believes that Ionis' treatment appears to be superior. The firm keeps an Outperform rating on Ionis.
10/06/16
BMOC
10/06/16
UPGRADE
BMOC
Outperform
Ionis Pharmaceuticals upgraded on reduced competition, valuation at BMO Capital
As noted earlier, BMO Capital upgraded Ionis (IONS) to Outperform from Market Perform. After Alnylam (ALNY) announced that it was discontinuing one of its Phase III RNAi drugs due to poor clinical outcomes, BMO Capital analyst Do Kim expects Ionis to benefit from the reduced competition. Kim recommends buying Ionis' stock on weakness today. Target to $48 from $42.
BIIB Biogen
$305.59

-0.4 (-0.13%)

09/28/16
JEFF
09/28/16
NO CHANGE
Target $50
JEFF
Buy
Jefferies parent survey shows interest in AveXis pivotal trial
Jefferies analyst Biren Amin conducted a survey of parents of spinal muscular atrophy patients amid investor questions surrounding AveXis' (AVXS) ability to enroll a pivotal trial with AVXS-101 given the open access program with nusinersen, the investigational drug being developed by Ionis Pharmaceuticals (IONS) and Biogen (BIIB). Parents value the option of nusinersen treatment but are also willing to enroll in clinical trials of AVXS-101, Amin tells investors in a research note, citing his survey of seven parents. A single arm trial of AVXS-101 was the most preferred clinical trial design for the upcoming Phase 3 of AVXS-101, he added. The analyst believes his parent responses suggest excitement over nusinersen but also a willingness to enroll into the AVXS-101 trials, especially if it is a single-arm trial. Parents were also attracted to AVXS-101 intravenous delivery, which could be a "meaningful advantage," Amin contends. The analyst keeps a Buy rating on AveXis with a $50 price target. The stock closed yesterday up 88c to $41.00. Amin caused a rally in AveXis shares on September 19 when writing about finding a video online of a spinal muscular atrophy baby walking that he believed to be a patient in the company's trial of AVXS-101.
09/28/16
BERN
09/28/16
NO CHANGE
BERN
Biogen likely to benefit from Lilly Alzheimer's drug results, says Bernstein
Bernstein analyst Aaron Gal says that the results of a trial of Eli Lilly's (LLY) Alzheimer's drug, solanezumab, due out in late 2016 or early 2017, are likely to impact perceptions of Biogen's (BIIB) Alzheimer's drug, aducanumab. The analyst expects Lilly's solanezumab "to show at least directional evidence" of cognitive improvement, although he is "less convinced" that the impact will be clearly statistically significant. The best results from Biogen's perspective will be if Lilly's drug shows "marginal success," according to Gal. However, statistically significant results are also good for Biogen, as they will show that reducing amyloid beta does mitigate Alzheimer's symptoms, the analyst stated. And if Lilly's drug completely fails, Biogen's drug "could well succeed," given the significant differences between them, wrote Gal,who gives Biogen's aducanumab a 65% chance of success. He keeps a $345 price target and Outperform rating on Biogen.
10/03/16
BMOC
10/03/16
NO CHANGE
Target $304
BMOC
Biogen potential trading opportunity into year-end, says BMO Capital
BMO Capital hosted a call with an expert on Alzheimers that may present a trading opportunity in Biogen (BIIB) shares as we approach sola Phase 3 and aducanumab titration data expected at year end. The expert said evidence supports the amyloid hypothesis of AD outweighs the evidence that undercuts it, but suggested that patient selection and trial design/execution key to demonstrating benefit to support regulatory approval. He estimated that Lilly's (LLY) EXPEDITION-3 trial has a ~60% probability of success, with Biogen's aducanumab greater than70% as long as rates of ARIA-E can be reduced with titration. Analyst Ian Somaiya believes positive Phase III Sola data could provide a positive read through to aducanumab and results in Biogen shares trading up 20-25%. If Sola misses, aducanumab's ability to clear beta amyloid oligomers & plaques and in our opinion a better trial design could limit downside in shares to approximately 10%. Somaiya rates Biogen a Market Perform with a $304 price target.
10/04/16
RBCM
10/04/16
NO CHANGE
Target $375
RBCM
Outperform
Biogen could rise $20 or more per share on SMA success, says RBC Capital
RBC Capital analyst Michael Yee expects the first presentation of data from Biogen's (BIIB) Phase III ENDEAR trial studying nusinersen, an investigational treatment for spinal muscular atrophy, or SMA, this week, potentially during the late breaker session at the WMS Congress on October 8. Biogen and partner Ionis Pharmaceuticals (IONS) already announced in August that the study in Type I infants hit the interim analysis and stopped early for positive data. The much larger opportunity in older children has data expected to read out in Spring 2017, noted Yee, who thinks Biogen can have upside from $10 to over $20 per share based on its SMA opportunity. Yee keeps an Outperform rating and $375 price target on Biogen shares.

TODAY'S FREE FLY STORIES

AKS

AK Steel

$6.54

-0.11 (-1.65%)

16:57
06/26/17
06/26
16:57
06/26/17
16:57
Hot Stocks
Breaking Hot Stocks news story on AK Steel »

Integrated Core…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

VNO

Vornado

$94.75

0.57 (0.61%)

16:51
06/26/17
06/26
16:51
06/26/17
16:51
Hot Stocks
Vornado sets July 7 as record date for JBG SMITH Properties spinoff »

Vornado announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATY

Cathay General

$36.99

0.08 (0.22%)

16:42
06/26/17
06/26
16:42
06/26/17
16:42
Syndicate
Breaking Syndicate news story on Cathay General »

Cathay General files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMCF

Emclaire Financial

16:39
06/26/17
06/26
16:39
06/26/17
16:39
Hot Stocks
Emclaire Financial appoints Engles as CFO, Lucco as risk and strategy chief »

Emclaire Financial,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TIER

TIER REIT

$17.60

-0.07 (-0.40%)

, ECA

Encana

$8.42

-0.04 (-0.47%)

16:36
06/26/17
06/26
16:36
06/26/17
16:36
Hot Stocks
TIER REIT acquires Texas office tower, sells remaining Louisville portfolio »

TIER REIT (TIER)…

TIER

TIER REIT

$17.60

-0.07 (-0.40%)

ECA

Encana

$8.42

-0.04 (-0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

AL

Air Lease

$36.84

0.28 (0.77%)

, BA

Boeing

$199.98

-2.25 (-1.11%)

16:34
06/26/17
06/26
16:34
06/26/17
16:34
Hot Stocks
Air Lease announces delivery of Boeing 737-800 to Royal Air Maroc »

Air Lease (AL) announced…

AL

Air Lease

$36.84

0.28 (0.77%)

BA

Boeing

$199.98

-2.25 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

PANL

Pangaea Logistics

$2.69

-0.1 (-3.58%)

16:34
06/26/17
06/26
16:34
06/26/17
16:34
Hot Stocks
Breaking Hot Stocks news story on Pangaea Logistics »

VR Advisory Services…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XL

XL Group

$43.62

0.21 (0.48%)

16:33
06/26/17
06/26
16:33
06/26/17
16:33
Hot Stocks
XL-Cayman waives financing condition for tender offers »

XL Group announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$17.08

1.28 (8.10%)

16:32
06/26/17
06/26
16:32
06/26/17
16:32
Hot Stocks
Breaking Hot Stocks news story on Valeant »

Paulson & Co. reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

TOPS

TOP Ships

$0.68

-0.12 (-15.00%)

16:31
06/26/17
06/26
16:31
06/26/17
16:31
Hot Stocks
TOP Ships reports $4.2M in cash, cash equivalents post reverse stock split »

TOP Ships reports its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTI

PCTEL

$6.95

-0.21 (-2.93%)

16:31
06/26/17
06/26
16:31
06/26/17
16:31
Hot Stocks
PCTEL raises quarterly dividend 10% to 5.5c per share »

This dividend will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

16:30
06/26/17
06/26
16:30
06/26/17
16:30
Options
Preliminary option volume of 13.3M today »

Preliminary option volume…

FNJN

Finjan Holdings

$3.62

-0.18 (-4.74%)

16:29
06/26/17
06/26
16:29
06/26/17
16:29
Syndicate
Finjan Holdings announces common stock offering, no amount given »

Finjan Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

16:20
06/26/17
06/26
16:20
06/26/17
16:20
Options
Closing CBOE SPX and VIX Index summary for June 26th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$88.17

3.34 (3.94%)

, LRLCY

L'Oreal

$43.61

1.53 (3.64%)

16:18
06/26/17
06/26
16:18
06/26/17
16:18
General news
On The Fly: Top stock stories for Monday »

The major averages began…

NSRGY

Nestle

$88.17

3.34 (3.94%)

LRLCY

L'Oreal

$43.61

1.53 (3.64%)

STOR

Store Capital

$23.11

2.34 (11.27%)

BRK.A

Berkshire Hathaway

$251,480.00

-320 (-0.13%)

BRK.B

Berkshire Hathaway

$167.47

0.25 (0.15%)

CAR

Avis Budget

$27.67

3.43 (14.15%)

GOOG

Alphabet

$952.27

-13.32 (-1.38%)

GOOGL

Alphabet Class A

$972.09

-14 (-1.42%)

HTZ

Hertz

$10.83

1.29 (13.52%)

AAPL

Apple

$145.82

-0.46 (-0.31%)

SGEN

Seattle Genetics

$56.55

-5.19 (-8.41%)

TKPYY

Takeda Pharmaceutical Co. Ltd.

$25.77

-0.11 (-0.43%)

SSYS

Stratasys

$24.39

-3.22 (-11.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

$NSD

NASDAQ Market Internals

16:17
06/26/17
06/26
16:17
06/26/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
06/26/17
06/26
16:16
06/26/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEWM

New Media

$13.62

0.27 (2.02%)

16:16
06/26/17
06/26
16:16
06/26/17
16:16
Hot Stocks
New Media rebrands propel business services unit, renames it UpCurve »

New Media Investment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALG

Alamo Group

$91.52

1.1925 (1.32%)

16:15
06/26/17
06/26
16:15
06/26/17
16:15
Hot Stocks
Alamo Group completes acquisition of Old Dominion Brush Company »

Alamo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BLUE

bluebird bio

$111.10

-0.9 (-0.80%)

16:13
06/26/17
06/26
16:13
06/26/17
16:13
Syndicate
bluebird bio announces offering of $350M of common stock »

bluebird bio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$53.74

-0.59 (-1.09%)

16:12
06/26/17
06/26
16:12
06/26/17
16:12
Periodicals
PayPal's Venmo tests debit card, Recode says »

PayPal's Venmo has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

KMPH

KemPharm

$3.40

0.05 (1.49%)

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Hot Stocks
KemPharm granted patent for KP746, a prodrug of oxymorphone »

KemPharm announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Conference/Events
Federal Reserve Bank President of San Francisco speaks on global growth »

San Francisco Federal…

SPLP

Steel Partners

$18.50

0.1 (0.54%)

, HNH

Handy & Harman

$28.50

-0.2 (-0.70%)

16:11
06/26/17
06/26
16:11
06/26/17
16:11
Hot Stocks
Steel Partners, Handy & Harman sign definitive merger agreement »

Steel Partners Holdings…

SPLP

Steel Partners

$18.50

0.1 (0.54%)

HNH

Handy & Harman

$28.50

-0.2 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$42.87

-1.47 (-3.32%)

16:10
06/26/17
06/26
16:10
06/26/17
16:10
Hot Stocks
Esperion says FDA confirms pathway for approval of bempedoic, ezetimib combo »

Esperion Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.